Business
Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1
Data presented at the AACR Annual Meeting 2021 MARLBOROUGH, Mass., April 10, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Data presented at the AACR Annual Meeting 2021\n\n\nMARLBOROUGH, Mass., April 10, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced new in vivo data showing intratumoral (IT) treatment with the murine PD-1 targeting INTASYL (mPH-762) inhibits tumor growth in a dose dependent fashion in PD-1 responsive and refractory models. Furthermore, on target efficacy was supported by modulation of immune cell populations toward antitumor phenotypes. The Company believes these data further support the potential for INTASYL mPH-762 to provide strong local immune checkpoint blockade (ICB), without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy. Phio is planning to advance this program with a first-in-human clinical study of PH-762 as a directly administered drug in patients with advanced melanoma at the Gustave Roussy Institute, which is scheduled to be initiated in the fourth quarter of 2021. \nLogo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg \n\"We are pleased to announce new in vivo data today that show INTASYL mPH-762 offered strong tumor control in Hepa 1-6 and CT26 models, which are PD-1 responsive and PD-1 refractory models, respectively. The modulation of key immune cell populations in the tumor microenvironment (TME) by local application of INTASYL mPH-762 provides further evidence that the desired efficacy to treat these cancers can be attained by direct intratumoral administration. Such local administration can have several advantages such as avoiding dose limiting systemic side effects which are often dose-limiting,\" stated Dr. Simon Fricker, Phio's VP of Research. \"These data further support our excitement around this asset and to bring PH-762 to patients, starting with our first clinical study later this year.\" \nAll INTASYL treatments were well tolerated. Treatment with mPH-762 inhibited tumor growth in both CT26 and Hepa 1-6 models in a dose dependent manner compared to control treated tumors, with mPH-762 providing tumor growth inhibition analogous to systemic anti-PD-1 monoclonal antibody (mAb) use. Hepa 1-6 is a PD-1 inhibition-responsive hepatoma model and CT26...